

(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number:	3235-0104			
Estimated average burden				
nours per response	e 0.5			

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Statement (Month/Day/Ye			3. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [NONE]				
09/09/20	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director 10% Owner Officer (give title Other (specify			Filed(Mon	5. If Amendment, Date Original Filed(Month/Day/Year)		
			below)	below)	Applicable I _X_ Form fi	ual or Joint/Group Filing(Check .ine) led by One Reporting Person ed by More than One Reporting Person	
Table I - Non-Derivative Securities Beneficially Owned							
2. Amount of Securities Beneficially Owned (Instr. 4)		wned	Form: Direct (D) or Indirect (I)	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
50,000 (1)				D			
d to the co lays a curr	ently vali	of informati id OMB cor	ion contained in t ntrol number.		·		
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivativ Security (Instr. 4)		Price of Derivative	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Title Amou		Security	(D) or Indirect (I) (Instr. 5)		
1	of securities d to the collays a curre e Securities. Date Exercing Expiration Month/Day/Year	Statement (Month/D 09/09/2016 2. Be (Ir of securities beneficialled to the collection of lays a currently value of Exercisable and Expiration Date Month/Day/Year)	Table 2. Amount of S Beneficially Or (Instr. 4) 50,000 (1) of securities beneficially owned directly of the collection of informate lays a currently valid OMB collection of the Exercisable and Expiration Date Month/Day/Year) Outer Expiration Title Amount of the Expiration Title Amount of Security of the Expiration of the Expiration Title Amount of Security of the Expiration of the Expirat	Statement (Month/Day/Year) O9/09/2016 Checkpoint Th 4. Relationship of Issuer (Check X_Director Officer (give titleledow) 2. Amount of Securities Beneficially Owned (Instr. 4) 50,000 50,000 50,000 Title and Amount of Securities Beneficially Owned (e.g., puts, calls, warr 3. Title and Amount of Securities Underlying Derivative Security Securities Underlying Derivative Securities Date Expiration Title Amount or Number of	Checkpoint Therapeutics, Indexestion	Checkpoint Therapeutics, Inc. [NONE]	

Reporting Owners

		Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
SALZMAN BARRY M C/O CHECKPOINT THERAPEUTICS, INC. 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK, NY 10014	X					

Signatures

/s/ James F. Oliviero, Attorney-in-Fact	10/04/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of restricted stock vest as follows: One-third on January 8, 2019, one-third on January 8, 2020, and one-third on January 8, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.